PBM
Psyence Biomedical Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$4.54
+2.48%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.3K | — | 4.3K | 240.00 | — |
| Gross Profit | (2.3K) | — | (4.3K) | (240.00) | — |
| Operating Expenses | |||||
| R&D Expense | 698.2K | 1.5M | 342.2K | 954.6K | 1.6M |
| SG&A Expense | 2.8M | 4.8M | 3.3M | 1.8M | 1.6M |
| General & Admin Expense | 1.3M | 4.5M | — | 1.7M | 1.6M |
| Selling & Marketing Expense | 314.1K | 218.5K | — | 80.6K | 7.0K |
| Other Expenses | 570.7K | 5.3K | — | — | (1.9M) |
| Total Operating Expenses | 4.0M | 6.2M | 3.7M | 2.8M | 1.3M |
| Cost and Expenses | 4.0M | 6.2M | 3.7M | 2.8M | 1.3M |
| Operating Income (EBIT) | (3.5M) | (6.2M) | (3.7M) | (2.8M) | (4.4M) |
| Non-Operating | |||||
| Interest Income | 72.8K | 263.4K | 95.8K | 2.1K | 1.6K |
| Interest Expense | 45.5K | 9.5K | 9.3K | 52.9K | — |
| Net Interest Income | 27.3K | 253.8K | 86.5K | (50.8K) | 1.6K |
| Other Non-Op Income/Expense | (22.2M) | (698.9K) | 4.7M | (48.4M) | 38.5K |
| Non-Operating Income (excl Interest) | (1.9M) | 689.4K | (4.7M) | 48.4M | (9.3M) |
| EBT (Pre-Tax Income) | (25.7M) | (6.9M) | 1.0M | (51.2M) | 8.0M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (26.3M) | (6.9M) | 1.0M | (51.2M) | 8.0M |
| Earnings from Cont. Ops | (26.3M) | (6.9M) | 1.0M | (51.2M) | (4.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (26.0M) | (6.9M) | 1.0M | (51.2M) | (4.3M) |
| Per Share | |||||
| Basic EPS | $1.64 | $0.00 | $1.78 | ($7.85) | ($0.64) |
| Diluted EPS | $1.62 | $0.00 | $1.78 | ($7.85) | ($0.64) |
| Revenue Per Share | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.5M | — | 568018 | 6.5M | 32.7M |
| Diluted Shares Outstanding | 1.5M | — | 568018 | 6.5M | 32.7M |
| Profitability Metrics | |||||
| EBITDA | (2.1M) | (6.9M) | 1.0M | (51.1M) | 10.8M |
| D&A | 2.5K | 5.3K | 4.3K | 240.00 | — |
| EBIT | (2.1M) | (6.9M) | 1.0M | (51.1M) | 10.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026